Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11890285 Combination therapies

Patent 11890285 was granted and assigned to Mirati Therapeutics on February, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Mirati Therapeutics

0

Current Assignee

Mirati Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Peter Olson0

James Gail Christensen0

David Briere0

Date of Patent

February 6, 2024

0

Patent Application Number

170296540

Date Filed

September 23, 2020

0

Patent Citations

US Patent 9840516 Substituted quinazolines as inhibitors of KRAS G12C

0

US Patent 8163763 Pyrimidine compounds, compositions and methods of use

0

US Patent 8426401 Azetidinyl diamides as monoacylglycerol lipase inhibitors

0

US Patent 9562019 Substituted pyridazines as EGFR and/or KRAS inhibitors

0

US Patent 10125134 KRas G12C inhibitors

0

Patent Primary Examiner

Noble E Jarrell

0

CPC Code

0

0

0

Patent abstract

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11890285 Combination therapies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool